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Abstract: In order to successfully cure patients with prostate cancer (PCa), it is important 
to detect the disease at an early stage. The existing clinical biomarkers for PCa are not 
ideal, since they cannot specifically differentiate between those patients who should be 
treated immediately and those who should avoid over-treatment. Current screening  
techniques lack specificity, and a decisive diagnosis of PCa is based on prostate biopsy. 
Although PCa screening is widely utilized nowadays, two thirds of the biopsies performed 
are still unnecessary. Thus the discovery of non-invasive PCa biomarkers remains urgent. 
In recent years, the utilization of urine has emerged as an attractive option for the  
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non-invasive detection of PCa. Moreover, a great improvement in high-throughput “omic” 
techniques has presented considerable opportunities for the identification of new 
biomarkers. Herein, we will review the most significant urine biomarkers described in 
recent years, as well as some future prospects in that field. 
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1. Introduction 
Cancer is one of the most critical health problems in our society, both in terms of morbidity and  
social impact. Prostate cancer (PCa) is the most commonly diagnosed cancer among European and 
American men (29% of all cases) [1,2]. Although PCa is a slow growing tumor that affects older men, 
it is still a lethal disease and is currently the second most common cause of cancer death among  
men [2]. The long latency period of this type of cancer and its potential curability make this disease a 
perfect candidate for screening [3]. 
Current screening techniques are based on a measurement of serum prostate specific antigen (PSA) 
levels and a digital rectal examination (DRE). A decisive diagnosis of PCa is based on transrectal  
ultrasound-guided prostate biopsies (PBs). The use of serum PSA as a cancer-specific detection test 
has some well-recognized limitations, such as a low positive predictive value (PPV).  
When PSA is 4.0–10.0 ng/mL, the PPV is 18% to 25% (mean, 21%), and when PSA is >10 ng/mL, 
the PPV is 58% to 64% (mean, 61%), when combined with a DRE as a screening tool this still results 
in approximately 66% negative PBs [4–6]. These patients are often subjected to repeat PSA 
measurements and PBs (the “over-diagnosis” problem). “Over-treatment,” through the detection of 
non-life-threatening tumors [7], especially in the so-called gray zone (serum PSA between  
4–10 ng/mL), represents yet another dilemma, as it is difficult to discriminate between patients with 
PCa and those with benign prostatic hyperplasia (BPH) or between those patients suffering from 
prostatitis and the results of urethral manipulation, which can also increase PSA levels [8]. Conversely, 
the prevalence of PCa in patients with PSA levels below the threshold of 4 ng/mL is around 15% 
resulting in undiagnosed cases of the disease [9,10]. As a consequence of the current screening 
parameters, approximately two thirds of the 1 million biopsies made annually both in the United  
States and in Europe are unnecessary [1,2]. There is therefore an urgent need for new and more 
effective biomarkers for PCa that can help to better identify which patients should undergo further 
diagnostic tests and also help to detect which patients will develop an aggressive tumor and, therefore, 
will need immediate treatment. 
2. Urine: A Source of Prostate Cancer Biomarkers 
The discovery of biomarkers is based on the following research principle: the comparison of 
physiological states, phenotypes or changes across control and case (disease) patient groups [11]. A 
key approach to biomarker discovery is to compare case versus control samples in order to detect 
statistical differences that can lead to the identification and prioritization of potential biomarkers. 
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Theoretically, this could be a single biomarker molecule, however, it is more likely to be a panel of  
up- and down- regulated molecules and/or proteins with altered post-translational modifications 
(PTMs) that differ in normal and disease states [12,13]. Here we have focused our biomarker 
classification system on the basis of their potential applications for screening, diagnosis, prognosis or 
prediction (see Box I). 
Box I: Types of Biomarkers Based on their Applications 
Screening/detection biomarkers, like serum PSA, are used to predict the potential occurrence of 
disease in asymptomatic men or those with non-disease-specific symptoms. 
Diagnostic biomarkers are used to make predictions for patients suspected of having a disease. An 
ideal diagnostic biomarker should enable an unbiased conclusion, particularly in patients without 
specific symptoms. It should fulfill several criteria: (i) high specificity for a given disease (low rate of 
false positives); (ii) high sensitivity (low rate of false negatives); (iii) ease of use (rapid procedure); 
(iv) standardization (consistent reproducibility); (v) clearly readable result for clinicians [13];  
(vi) cost-effectiveness; and (vii) ability to be quantified in an accessible biological fluid or sample. 
Prognostic biomarkers are used to predict the overall outcome of a patient, regardless of therapy. 
Predictive biomarkers are used to identify subpopulations of patients who are most likely to respond 
to a given therapy. A predictive biomarker can be a target for therapy. 
In recent years interest in searching for new biomarkers obtainable by non-invasive means has 
increased significantly. For centuries, physicians have attempted to use urine for the non-invasive 
assessment of disease. Urine is produced by the kidneys and allows the human body to eliminate waste 
products from the blood. Urine may contain information not only from kidney and urinary tracts, but 
also from distant organs via plasma obtained through glomerular filtration. The analysis of urine could, 
therefore, allow the identification of biomarkers for both urogenital and systemic diseases. 
The main function of the prostate gland is the secretion of prostatic fluid, which on ejaculation is 
combined with seminal vesicle derived fluid to promote sperm activation and function [14]. The gentle 
massage of each side of the prostate gland during DRE stimulates the release and movement of 
prostatic fluids and detached epithelial cells into the urethra [14] (Figure 1). These fluids can contain 
both cells and secretions originating in PCa [15]. PCa cells were first described in voided urine by 
Papanicolaouin 1958 [16], however they appear to be fragile and low in number [17] underlying the 
need for careful collection, manipulation and storage of urine prior to analysis. Urine collection can be 
accomplished without a disruption of standard clinical practice and can be sampled multiple times 
throughout the course of prostatic disease. Nevertheless, using urine for the discovery of biomarkers 
presents some important technical challenges. 
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Figure 1. (A) Anatomical location of the prostate; (B) Prostate cancer cells;  
(C) Biomarkers found in urine. Based on their descriptions, biomarkers can be divided into 
the following groups: DNA-based, RNA-based, and protein-based. Of late, urinary 
exosomes, which are secreted vesicles that contain proteins and functional RNA and 
miRNA molecules, have emerged as a novel approach to acquiring new PCa biomarkers. 
 
The search for effective biomarkers has principally included transcriptional profiling, DNA 
methylation, metabolomics, fluxonomics, and more recently, proteomics [18]. Emerging biomarkers 
have the potential to be developed into new and clinically reliable indicators, which will have a high 
specificity for the diagnosis and prognosis of PCa. Ideally biomarker acquisition will be less invasive 
than current clinical means, and will be useful for screening men for PCa, and be able to guide patient 
management to provide maximum benefits while minimizing treatment-related side effects and  
risks [19]. This review focuses on published data referring promising DNA, RNA, miRNA, protein 
and metabolite based urine biomarkers (Table 1) and highlights exosomes as a new source of PCa  
urinary biomarkers. 
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Table 1. Summary of PCa biomarkers in the literature. 





Enzyme involved in branched  
chain fatty acid oxidation 
Over-expressed in PCa (also in HGPIN)  
and in some other carcinomas, both  
at RNA and protein level 
Diagnostic (in gray zone) and prognostic 
Tissue, blood and 
urine 
[20,21] 
ANXA3 Annexin A3 Calcium and phospholipid binding protein 
Presence in urinary exosomes and  
proteasomes. Lower production in  
PCa than in BPH, HGPIN and benign 
Prognostic (able to stratify a large group of 
intermediate-risk patients into high- and 
low-risk subgroups) 




Tumor suppressor. Promotes  
rapid degradation of CTNNB1  
and participates in Wnt signaling  
as a negative regulator. 
APC methylation higher in PCa than in  
BPH. Methylation level correlates  
positively with Gleason score 
Diagnostic and prognostic 
Tissue and Urine 
DNA 
[25] 
AR Androgen receptor 
Receptor for androgen  
stimulation of prostate. 
Over-expression associated with poor  
prognosis prostate cancer and metastasis 
Prognostic 
Tissue RNA and 
IHC 
[26–28] 
AURKA Aurora kinase. 
Aurora kinase. AURKA is a  
centrosome-associated serine/ 
threonine kinase involved in  
mitotic chromosomal segregation. 
Amplified and over-expressed in certain  
types of poor prognosis prostate cancer 
Prognostic 




Alpha-2-glycoprotein 1, zinc 
binding. Alias. ZAG 
Stimulates lipid degradation in  
adipocytes and causes the extensive  
fat losses associated with some 
advanced cancers. May bind  
polyunsaturated fatty acids. 
Over-expressed in PCa. Low AZGP1  
expression predicts for recurrence in  
margin-positive, localized PCa 
Diagnostic, prognostic 




v-raf murine sarcoma viral 
oncogene homolog B1 
Belongs to the raf/mil family of  
serine/threonine protein kinases  
and is involved in the regulation  
of the MAP kinase/ERKs signaling  
pathway, which affects cell  
division, differentiation. 
SLC45A3-BRAF fusion gene, mutations and  
gain in prostate cancer 
Diagnostic and therapeutic target 





dependent protein kinase 
kinase 2. 
AR target gene promoting  
biosynthesis and glycolysis 
Down-regulation of calcium/ 
calmodulin-dependent protein kinase  
kinase 2 by androgen deprivation induces  
castration-resistant prostate cancer. 
Prognostic Tissue RNA [38–40] 
CDH1 
Cadherin 1, type 1,  
E-cadherin (epithelial) 
Epithelial cell - cell adhesion molecule 
Reduced production in 50% of tumors.  
E-cadherin production by epithelial  
cells has been shown to predict PCa prognosis 
Prognostic (correlated with grade, tumor 
stage, and survival) 
Tissue [41,42] 
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Table 1. Cont. 
Gene Description Gene type Expression Type of biomarker Sample References 
CLU Clusterin 
Function unknown, but is thought  
to be involved in several basic  
biological events such as cell 
death and tumor progression. 





Cysteine-Rich Secretory  
Protein 3 
Secreted protein produced in the  
male reproductive tract, is involved  
in sperm maturation 
Large amounts have been detected  
in seminal plasma. Over-expressed  
in HGPIN and PCa. 
Prognostic Tissue [47,48] 
EPCA Early Prostate Cancer Antigen Nuclear matrix protein Over-expressed in PCa Diagnostic (for predicting repeated BP) Tissue and blood [49,50] 
EPCA-2 Early Prostate Cancer Antigen 2 Nuclear matrix protein Over-expressed in PCa 
Diagnostic and Prognostic (differentiate 




Folate hydrolase 1/ Prostate  
Specific Membrane Antigen 
Type II membrane protein.  
1/N-acetylated-alpha-linked 
acidic dipeptidase 
Over-expressed in PCa compared  
to BPH and normal 
Diagnostic. Imaging marker  
and target for therapy 




Golgi membrane  
protein 1 (GOLPH2) 
Cis-Golgi membrane protein  
of unknown function 




Enzyme involved in protecting  
DNA from free radicals 
Loss of GSTP1 expression due to  
the promoter hypermethylation (>90% of PCa).  
Correlates with the number of cores 
found to contain PCa 
Diagnostic (indicator for repeat biopsy) 
Tissue and urine 
DNA 
[56,57] 
HPN Hepsin Membrane serine protease 
Over-expressed in 90% PCa tumors  
(highly produced in HGPIN  
and PCa compared with BPH) 
Diagnostic Tissue [58,59] 
IL-6 Interleukin-6 
Cytokine secreted by a variety  
of cell types, is involved in the  
immune and acute-phase response 
Increased concentrations of IL-6  
and IL-6R in metastatic  
and androgen-independent PCa 
Diagnosis and Prognostic Blood [60–62] 
IMPDH2 
IMP (inosine 5'-monophosphate) 
dehydrogenase 2 
Myc target gene associated  
with nucleotide biosynthesis 
Increased serum level associated  
with the clinicopathological  
features of the patients with PCa 
Diagnostic Blood [63] 
KLK2 Human Kallikrein 2 Secreted serine protease Over-expressed during PCa progression Diagnostic and Prognostic Tissue and blood [64,65] 
KLK3 (PSA) 
Kallikrein-related peptidase 3 
(Prostate-Specific Antigen) 
Secreted serine protease.  
Serum level of this protein,  
called PSA in the clinical setting,  
is useful in the diagnosis  
and monitoring of PCa. 
Increased expression associated with malignant PCa Diagnostic Blood, urine [66] 
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Table 1. Cont. 




One of fifteen kallikrein subfamily  
members located in a  
cluster on chromosome 19 
Increased expression associated with malignant PCa Prognostic Tissue RNA and IHC [67,68]. 
MAP3K5 
Mitogen-activated protein kinase 
kinase kinase 5 
Signaling cascade Increased expression associated with PCa Prognostic Tissue RNA and IHC [69] 
MKI67 
Encoding antigen identified  
by monoclonal antibody  
Ki-67 
Tumor growth marker, encodes  
a nuclear protein that is associated  
with and may be necessary  
for cellular proliferation 
Increased expression associated  
with malignant prostate cancer 
Prognostic Tissue [70–72] 
MMP26 
Matrix metallo  
peptidase 26 
Involved in the breakdown of extracellular 
matrix in normal physiological processes  
and cancer metastasis. 
Highest expression in HGPIN  
and decline in cancer, possible  
involvement in formation of early cancer. 
Progression Tissue RNA [73–76] 
MMP9 Matrix metallo proteinase 9 
Implicated in invasion and metastasis  
of human malignancies 
Over-expressed in PCa Diagnostic Urine [77,78] 
OR51E2/PS
GR 
Prostate Specific  
G-coupled Receptor 
Receptors coupled to heterotrimeric  
GTP-binding proteins 
Over-expressed in PCa Diagnostic Tissue and urine [79–81] 
PAP 
Human Prostatic acid 
phosphatase 
Enzyme Over-expressed in PCa and in bone metastasis 
Diagnostic and Prognostic  
of PCa bone metastasis 
Blood and urine [82,83] 
PCA3 Prostate Cancer Gene 3 Non coding mRNA Prostate specific and highly up-regulated in PCa Diagnostic (indicator for repeat biopsy) Tissue and urine [84–93] 
PDIA3 
Protein disulfide isomerase 
family A, member 3. 
Endoplasmic reticulum that  
interacts with lectin chaperones  
calreticulin and calnexin to  
modulate folding of newly  
synthesized glycoproteins. 
Increased expression associated with malignant PCa Prognostic Tissue RNA and IHC [69] 
PSCA Prostate Stem Cell Antigen Membrane glycoprotein 
Specific production in the prostate and  
possible target for therapy 
Prognostic (correlated with  
higher Gleason score, higher stage,  
and the presence of metastasis) 
Tissue and blood [94,95] 
RARB Retinoic acid receptor, beta 
Binds retinoic acid. Mediates signalling  
in embryonic morphogenesis,  
cell growth and differentiation. 
DNA methylation Prognostic 




Ras association (RalGDS/ 
AF-6) domain family  
member 1 
Potential tumor suppressor. Required  
for death receptor-dependent apoptosis 
DNA methylation Prognostic 
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Table 1. Cont. 
Gene Description Gene type Expression Type of biomarker Sample References 
Sarcosine Sarcosine 
N-methyl derivative of  
the amino-acid glycine 
Seems to be differentially expressed  
metabolite elevated during  
PCa progression to metastasis 
Prognostic Urine and blood [98] 
SPINK1 
Serine peptidase inhibitor, Kazal 
type 1 
Serine peptidase inhibitor 
Overexressed in a portion of  
non-ETS translocated tumors 
Diagnostic Urine, tissue [54,99] 
TERT Telomerase reverse transcriptase 
Maintains the telomeric ends of  
chromosomes and if telomerase is active,  
cancer cells may escape cell cycle  
arrest and replicative senscence 
Amplification in PCa, significative  
association with Gleason score 
Prognostic Urine and blood [57,100,101] 
TGFB1 Transforming growth factor-b1 
Growth factor involved in  
cellular differentiation, immune 
response, angiogenesis, and proliferation 
Role of TGF1 in PCa progression. 
Prognostic (Correlation with  
tumor grade and stage and  
lymph node metastasis) 
Tissue and blood [62,102,103] 
TIMP4 
TIMP metallopeptidase inhibitor 
4 
Inhibitors of the matrix metallo  
proteinases 
Highest expression in HGPIN 
and decline in cancer, possible  
involvement in formation of early cancer. 
Progression Tissue RNA [73–75] 
TMPRSS2:E
RG 
5' UTR of the  
prostate-specific androgen 
regulated transmembrane 
protease serine2 and v-ETS 
erythroblostosis virus E26 
oncogene homolog 
Gene fusion; androgen drives  
the expression of ETS-TF  
and causes tumor proliferation 
The most common gene fusion  
in PCa. Over-expressed PCa  
and related to PCa aggressiveness 
Prognostic for aggressive PCa and  
detection of PCa 




Urokinase and Receptor 
Degradation of extra cellular matrix Over-expressed in BPH and PCa vs benign 
Prognostic (increased uPA and uPAR  
in PCa patients with bone metastasis) 
Tissue and blood [107,108] 
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2.1. DNA-Based Urinary Biomarkers 
DNA-based biomarkers include single nucleotide polymorphisms (SNPs), chromosomal aberrations, 
changes in DNA copy number, microsatellite instability, and altered promoter-region methylation [109]. 
The epigenetic silencing of the glutathione-S-transferase P1 (GSTP1) gene is the most common 
(>90%) genetic alteration so far reported in PCa [110–112]. Methylation-specific polymerase chain 
reaction (MSP) methods allowed the successful detection of GSTP1 methylation in urine, and 
ejaculates from PCa patients. A possible drawback is the high frequency of GSTP1 methylation in 
patients with high-grade prostatic intraepithelial neoplasia (HG PIN) and in patients with negative or 
suspicious PB. Further follow-up is needed to determine whether such cases are false positives or part 
of the significant number of under-diagnosed cancer cases in PB. Recently, Costa et al. observed 
significantly different methylation levels of the genes protocadherine 17 (PCDH17) and transcription 
factor 21 (TCF21) in PCa tissue compared to cancer free individuals, providing 83% sensitivity and 
100% specificity for cancer detection. However while absolute specificity was retained in urine 
samples, sensitivity was only 26% [113]. In comparison, Daniunaite et al., (2011) report the high 
sensitivity of DNA methylation biomarkers in urine, especially that of RASSF1 (Ras association 
(RalGDS/AF-6) domain family member 1) and RARB (retinoic acid receptor beta) for the early and 
non-invasive detection of PCa. Thus, results this far suggest that methylated genes can serve as useful 
markers for PCa [97]. 
2.2. RNA-Based Urine Biomarkers 
RNA-based biomarkers include coding and non-coding transcripts and regulatory RNAs, such as 
microRNAs (miRNAs) [109]. Improvements in RNA microarray platforms, quantitative PCR (qPCR), 
and the development of new high-throughput technologies, such as next-generation sequencing (NGS), 
allow us to better understand the expression profiles of single cells, populations of cells and specific 
tissues, while also allowing comparisons between different pathological conditions. In recent years, a 
wide range of promising PCa biomarkers that are not only prostate-specific, but also differentially 
expressed in prostate tumors, have been identified. 
After PSA, Prostate Cancer Antigen 3 (PCA3), is the only biomarker approved by the Food and 
Drug Administration (FDA), and is utilised in a commercially available test under the name 
PROGENSA® PCA3 (Gen-Probe, San Diego, CA, USA) [84]. PCA3 was first identified in 1999 [85]. 
The PCA3 gene encodes a non-coding RNA (ncRNA) (see Box II) that is over-expressed in 95% of all 
primary PCa specimens. Some of its potential applications include testing as an alternative to a first PB 
and, aiding the decision whether to repeat a PB in men with high serum PSA levels and previously 
negative biopsies [86,87]. The measurement of PCA3 mRNA vs. PSA mRNA in urine was first 
proposed by Hessels et al. [88]. Later on, this study was verified in a large, European multicenter 
study, which concluded that PCA3 possessed potential as an aid in PCa diagnosis [89]. The assay 
consists of a transcription-mediated amplification, which demonstrates 69% sensitivity, 79% specificity, 
and an area under the curve (AUC) value of 0.75 [90]. Currently, a PCA3 score (PCA3-to-PSA ratio) 
cut-off of 35 has been adopted, which combines the greatest cancer sensitivity and specificity  
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(54% and 74%, respectively) [91]. However, more recent studies have shown that a lower cut-off score 
of 25 might be preferable [92]. 
Prostate Specific Membrane Antigen (PSMA) was first proposed as a serum prognostic marker for 
PCa in 1999; however, its use is controversial [114]. A Dual-Monoclonal Sandwich Assay for PSMA 
was developed to be used on tissues, seminal fluid and urine [115]. Levels of PSMA in serum have 
been suggested to be useful for distinguishing between BPH and PCa [116], and subsequently the 
same results were found for urinary PSMA [117]. PSMA is present in exosomes in urine samples from 
PCa patients after therapy [118]. Our group has evaluated the utility of PSMA mRNA transcripts in 
conjunction with PCA3 and Prostate Specific G-coupled Receptor (PSGR) in the PSA diagnostic “gray 
zone” of 4–10 ng/mL when no prior biopsy information was available. We demonstrated that the 
prediction of PCa improved significantly for PSMA (0.74), while PSGR (0.66) and PCA3 (0.61) 
showed a similar performance [119]. However, the use of PSMA has not yet been adopted in  
clinical practice. 
Another promising RNA-based urinary biomarker is encoded by a fusion gene formed as a result of 
a translocation between the androgen-regulated transmembrane protease, serine 2 (TMPRSS2) gene 
transcriptional promoter and the ETS related oncogene (ERG), resulting in an androgen-regulated 
TMPRSS2–ERG fusion gene that is highly specific for PCa and can be found in approximately half of 
all white PCa patients [120]. Hessels et al., analyzed TMPRSS2-ERG fusion transcripts in urinary 
sediments and demonstrated a sensitivity of 37% and a specificity of 93% for the prediction of  
PCa [104]. Moreover, TMPRSS2-ERG was correlated with pathological stage [121], Gleason  
score [121,122] and with PCa death [122]. Additional marker analysis in a multiplex detection system 
could further improve sensitivity and specificity. 
2.3. miRNA-Based Urine Biomarkers 
The discovery of miRNAs has opened up a new field in cancer research with potential novel 
applications in diagnostics and therapy [123]. MicroRNAs are short, ncRNAs with an average length 
of 22 nucleotides [124] (see Box II). After transcription they fold into hairpin structures before being 
processed into mature miRNAs that bind to complementary sequences in mRNAs to alter protein 
expression. Currently, 1600 precursor and 2042 mature human miRNAs are registered in miRBase 
Release 19 (August 2012), and each of these may target up to 1000 gene sequences [125]. This 
provides a complex layer of control in for example, signaling pathways involved in the regulation of 
cellular functions, ranging from the maintenance of “stemness” to differentiation and tissue 
development, and from the cell cycle to apoptosis and metabolism [126–128]. Thus, aberrant 
expression of miRNAs can impact deeply on multiple features of cell biology resulting in complex 
downstream pathological events, such as cancer [129]. Specific miRNAs have been shown to be 
abnormally expressed in tumor tissues, playing important roles in cancer onset and disease progression 
through the targeting of cancer-relevant genes [130]. 
miRNA profiles of different tissues have been reported to be more predictive than mRNA 
characterization to such an extent that poorly differentiated tumors of uncertain origin could be 
classified on the basis of miRNAs expression [131]. MiRNAs are very stable and are detectable in 
biopsies, serum, and other fluids, such as urine [132]. Between 200 and 500 miRNAs were detected by 
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qPCR in different human body fluids, such as plasma, urine and breast milk [133]. Mitchell et al., 
found that the serum levels of the miRNA “miR-141” distinguished patients with advanced PCa from 
healthy controls [134]. Other recent studies have demonstrated that circulating miR-141 levels were 
correlated to aggressive PCa [135], and that miR-96 and miR-183 expression in urine were well 
correlated to urothelial carcinoma (UC) stage and grade, serving as promising diagnostic tumor 
markers capable of distinguishing between UC patients and non-UC patients [136]. However, only one 
study has been published linking miRNAs from urine with PCa. In that study, the analysis of five 
selected miRNAs in urine samples found that miR-107 and miR-574-3p were present at a significantly 
higher concentration in the urine of PCa patients compared to controls [137]. 
In PCa most of the circulating miRNA studies which have found associations between miRNA 
populations and aggressive and metastatic disease have been conducted using serum or plasma and 
need to be validated in larger patient and control samples [130]. Specific miRNA patterns in the urine 
may also reflect early or advanced PCa disease, but while urine miRNAs have been investigated in 
bladder and kidney cancer, no comprehensive studies for miRNA in PCa urine have been reported so 
far. Therefore, despite the obvious potential for circulating and urine miRNAs in diagnostic, 
prognostic, and predictive applications, clinical implementation of a non-invasive miRNA test for PCa 
is still a distant goal [138]. 
Box II: Non-coding RNA 
A “central dogma” of molecular biology was that genetic information flowed in one direction with 
proteins as the end product. However, growing evidence has emerged to describe the role of RNAs that 
are not translated into proteins. These ncRNAs comprise microRNAs, anti-sense transcripts and other 
transcriptional units containing a high density of stop codons and lacking any extensive “Open 
Reading Frame” (ORF) [139]. Several types of ncRNAs have been implicated in gene regulation via 
modification of the chromatin structure, alterations to DNA methylation, RNA silencing, RNA  
editing, transcriptional gene silencing, post-transcriptional gene silencing, and enhancement of gene  
expression [140–142]. It is becoming clear that these RNAs perform critical functions during 
development and cell differentiation [139]. The roles that small-ncRNAs, such as miRNAs and small 
interfering RNAs (siRNAs), play in gene silencing have been well-studied, and they have been 
reported to be aberrantly expressed in many cancers [140]. ncRNAs are thus emerging as a new class 
of functional transcripts in eukaryotes. 
2.4. Protein-Based Urine Biomarkers 
Protein-based biomarkers include cell-surface receptors, tumor antigens (such as PSA), 
phosphorylation states, carbohydrate determinants and peptides released by tumors into serum, urine, 
sputum, nipple aspirates, or other body fluids [109]. Proteins secreted by cancer cells can be essential 
in the processes of differentiation, invasion and metastasis [143,144]. Secreted proteins or their 
fragments present in body fluids, such as blood or urine, can be measured via non-invasive or 
minimally invasive assays. To date, only a few studies have analyzed cancer secretomes. However, the 
results with regards to the discovery of biomarkers are rather exciting [145]. 
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Recently the detection of under-expressed PSA protein levels in urine has been reported [146–149]. 
Bolduc et al. compared a small cohort of urine samples collected (without previous DRE) from 
“normal”, BPH and PCa men, and the data suggested that the ratio of serum PSA to urine PSA could 
possess diagnostic value [146]. The same idea was also suggested in another independent study where 
PSA levels were also determined in urine. In that study, no differences between urinary PSA pre- and 
post-PM were found [150]. Later, Drake et al. [14] performed a study in which they focused on the 
characterization of PSA and Prostatic Acid Phosphatase (PAP) using an Enzyme-Linked ImmunoSorbent 
Assay (ELISA) assay on post-DRE urine samples. They found a clear trend towards lower levels of 
expression for both proteins in their cancer samples.  
Another protein-based candidate is Annexin A3 (ANXA3), which is a calcium-binding protein with 
an associated decreased production in PCa cells. The analysis of ANXA3 using Western blots (WB) of 
urine samples showed significantly lower values in PCa patients as compared with BPH patients. 
When this marker was combined with serum PSA there was improved sensitivity and high specificity 
compared to total PSA, with an AUC of 0.81 [151]. Katafigiotis et al., looked at urine samples from 
127 PCa patients obtained after DRE, measuring zinc α 2-glycoprotein (ZAG) by WB. Receiver 
operating characteristic (ROC) curve analysis showed a significant predictive ability for PCa with 
AUCs of 0.68 [32]. 
Recent advances in liquid chromatography (LC) and two dimensional gel electrophoresis (2D-GE), 
in combination with mass spectrometry (MS) have significantly facilitated the challenging detection of 
proteins in body fluids [152]. High-throughput proteomic analysis of biological fluids such as urine, 
has recently become a popular approach for the identification of novel biomarkers, due to the reduced 
complexity compared to serum [153]. However, only a limited number of studies have focused on PCa.  
One of the first proteomic urine profiling experiments for the detection of PCa was performed by 
Rehman et al., using a gel-based strategy comparing PCa and BPH samples [154]. They identified 
S100A9 (calgranulin B, MRP-14) as a possible biomarker. However, this data was not verified in an 
independent study. More recently, several studies have focused on the characterization of urine 
samples in a high-throughput manner. Teodorescu et al., performed a pilot study for PCa using 
Capillary Electrophoresis (CE) coupled with MS and to define a potential urinary polypeptide pattern 
with 92% sensitivity and 96% specificity [155]. Later, the same group described a refinement of the 
PCa specific biomarker pattern using 51 PCa and 35 BPH urine samples [156]. The model, containing 
12 potential biomarkers, resulted in the correct classification of 89% of the PCa cases and 51% of the 
BPH cases in a second blind cohort of 213 samples. The inclusion of age and free PSA parameters 
increased the sensitivity and specificity to 91% and 69%, respectively. M’Koma and collaborators 
performed a large-scale proteomic analysis of BPH, HGPIN and PCa urine samples [157]. Using 
Matrix Assisted Laser Desorption Ionization-Time of Flight (MALDI-TOF) analysis, the group 
reported 71.2% specificity and 67.4% sensitivity for discriminating between PCa and BPH, while they 
also reported a specificity of 73.6% and a sensitivity of 69.2% for discriminating between BPH and 
HGPIN. Finally, Okamoto et al. used Surface Enhanced Laser Desorption Ionization Time of Flight 
(SELDI-TOF) analysis coupled to MS to analyze post-DRE urine samples. They obtained a heat map 
with 72 peaks, which could distinguish PCa from benign lesions with a sensitivity of 91.7% and a 
specificity of 83.3% [158]. However, although there have been an increasing number of publications in 
the proteomic urine PCa field, most of this data has not been verified in independent studies. 
Int. J. Mol. Sci. 2013, 14 12632 
 
 
2.5. Metabolite-Based Urine Biomarkers 
Metabolomics is a recently incorporated–omic approach that identifies metabolites using techniques 
similar to proteomics. Urinary metabolomic profiles have recently drawn a lot of attention owing to a 
debate regarding their possible role as potential clinical markers for PCa [159]. Using 262 clinical 
samples, including 110 urine samples, Seekumar et al. performed a major study in the field of PCa 
metabolomics: 1126 metabolites were analyzed using LC and gas chromatography MS [98], and a 
profile was identified that was able to distinguish between benign, clinically localized PCa and 
metastatic cancer. Sarcosine and the N-methyl derivative of the amino acid glycine were found at 
highly increased levels in PCa and were associated with disease progression to metastasis. However, 
validation of this metabolite has failed to reproduce these findings [160], and therefore, the utility of 
sarcosine is still under discussion. 
2.6. Urine Biomarker Panels 
Although a great number of urine biomarkers have been documented in large screening programs, 
there are only a few studies that take into account the heterogeneity of cancer development based on a 
diagnostic profile. Since a single marker may not necessarily reflect the multifactorial nature of PCa, a 
combination of various biomarkers in conjunction with clinical and demographic data could improve 
performance over the use of a single biomarker [161–163]. Adding extra genes into the “fingerprint” 
results in an additional layer of statistical complexity prompting new developments in biostatistics and 
bioinformatics [109].  
Table 2 summarizes the most significant studies that have used panels of urinary biomarkers. 
Hessels et al. performed a study on 108 patients using urine sediments, where the authors combined 
PCA3 with TMPRSS2-ERG fusion status. Combining both markers remarkably increased the 
sensitivity for the detection of PCa [104]. In this sense, the combination of TMPRSS2-ERG and PCA3 
and serum PSA was described as a method that could predict PCa with 80% sensitivity and 90% 
specificity [161] and help urologists in the decision to take PBs [162]. Furthermore, TMPRSS2-ERG in 
combination with PCA3 enhances serum PSA as a marker for defining PCa risk and clinically relevant 
cancer on PB [163]. More recently, Lin and collaborators also combined these markers and demonstrated 
that they can be used to stratify the risk of having aggressive PCa [54]. Another important study came 
from Lexman et al., who developed a multiplex model that measured the expression of seven putative 
PCa biomarkers and found that a combination of Golgi Membrane Protein (GOLPH2), Serine 
Peptidase Inhibitor Kazal type 1 (SPINK1) and PCA3 transcript expression with TMPRSS2-ERG  
fusion status was a better predictor of PCa than PSA or PCA3 alone (65.9% sensitivity and 76.0% 
specificity) [54]. Ouyang et al., have developed a duplex qPCR assay for the detection of PCa, based 
on the quantification of alpha-methylacyl-CoA racemase (AMACR) and PCA3 in urine sediments, 
while Talesa et al. analyzed PSMA, Hepsin (HPN), PCA3, UDP-N-acetyl-alpha-D-galactosamine:  
polypeptide N-acetylgalactosaminyltransferase 3 (GalNAC-T3) and PSA using qPCR and concluded 
that the best combination of biomarkers for predictors of PCa included urinary PSA and PSMA [117].  
Rigau et al. [119] have developed a multiplex test based on the combination of qPCR analysis of 
PCA3, PSGR, PSMA levels in urine with serum PSA protein levels in a prospective study using post-
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DRE urine samples from 57 PCa patients and 97 age-matched benign controls. They observed that by 
using this model, it is possible to reduce the number of unnecessary PB by 34% [119]. A multiplexed 
quantitative methylation-specific PCR assay consisting of three different methylated genes: GSTP1, 
RARB and APC was recently tested in a prospective multicenter study using post-DRE urine samples 
from 178 PCa patients and 159 controls. The predictive accuracy AUC of the assay for detecting PCa 
was 0.72. This was only a marginal gain in predictive ability with respect to biopsy outcome as 
compared to total PSA and DRE alone [164]. Although these combined biomarkers significantly 
improve sensitivity and specificity over single biomarkers, to our knowledge none of these panels have 
yet been established in clinical practice. 
Table 2. Summary of the most significant studies that have used panels of urine 
biomarkers for PCa detection. 
Biomarker type Study Marker PCa/study Sens. Spec. AUC 
DNA 
Hoque et al., 2005 [112] p16, ARF, MGMT, GSTP1 73 87% 100% ND 
Rouprêt et al., 2007 [110] GSTP1, RASSF1A, RARB, and APC 95/133 87% 89% ND 
Vener et al., 2008 [165] GSTP1, RARB and APC 54/121 55% 80% 0.69 
Payne et al., 2009 [166] GSTP1, RASSF2, HIS1H4K, TFAP2E 192 94% 27%  
Baden et al., 2009 [164] GSTP1, RARB and APC 178/159 ND ND 0.72 
Costa et al., 2011 [113] PCDH17, TCF21 318 26% 100%  
mRNA 
Hessels et al., 2007 [104] PCA3 and TMPRSS2:ERG 78/108 73% 52% ND 
Laxman et al., 2008 [54] 
PCA3, GOLPH2, SPINK1 and 
TMPRSS2:ERG 
152/257 66% 76% 0.76 
Ouyang et al., 2009 [167] AMACR and PCA3 43/92 72% 53% ND 
Talesa et al., 2009 [117] 
PSMA, HPN, PCA3, GalNAC-T3  
and serum PSA 
 49% ND ND 
Rigau et al., 2010 [81] PCA3 and PSGR 73/215 96% 34% 0.73 
Rigau et al., 2011 [119] PSMA, PSGR, PCA3 and serum PSA 57/154 96% 50% 0.82 
Salami et al., 2011 [168] PCA3, TMPRSS2:ERG and serum PSA 15/45 80% 90% 0.88 
Jamasphvili et al., 2011 [169] PCA3, AMACR, TRMP8, SMSB 104 72% 71%  
Nguyen et al., 2011 [170] TMPRSS2:ERG subtypes 101 35% 100%  
Tomlins et al., 2011 [171] PCA3 and TMPRSS2:ERG 






Rehman et al., 2004 [154] 
ENO1, IDH3B, B2M, A1M, PRO2044 
and S100A9 (Calgranulin_B/MRP-14) 
6 PC (12)    
Theodorescu et al., 2005 [155] Proteinpolypeptide 26/47 92% 96%  
M'Koma et al., 2007 [157] 130 m/z 89/407 81% 80%  
Theodorescu et al., 2008 [156] 12 protein pannel + age + serum PSA 
86 Training set 
+ 213 
validation set 
91% 62%  
Okamoto et al., 2008 [158] 72 masspicks 57 / 113 91% 83%  
Mixture 
Cao et al., 2010 [172] 
mRNA, protein and metabolite  
(PCA3, TMPRSS2: ERG, ANXA3, 
Sarcosine, and urine PSA) 
86/131 95% 50% 0.86 
Prior et al., 2010 [173] 
mRNA (AMACR/MMP2) ,DNA 
(GSTP1/RASSF1A) and PSA  
in serum and urine 
34/113 57% 97% 0.79 
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2.7. Exosomes as a Source of Urine Biomarkers 
Exosomes are small, secreted membranous vesicles formed in multivesicular bodies through an 
inward budding mechanism that encapsulates cytoplasmic components [174]. For many years 
exosomes were thought to be organelles for the removal of cell debris or obsolete surface molecules 
from the cell. However, further investigations have revealed a role for exosomes in inter-cellular 
communication. In the last five years, several studies have demonstrated that exosomes may be 
secreted by multiple cell lines and cell types, including tumor cell lines, stem cells and neuronal  
cells [175]. In addition, exosomes have been identified in most body fluids, such as blood, urine and 
ascites [175]. The discovery of their nucleic acid contents, such as mRNA, small ncRNA, miRNA and 
mitochondrial DNA (mtDNA), which can be transported to other cells [176], represents a major 
breakthrough, and several studies have indicated that they can play a novel role as regulators in  
cell-cell communication during diverse biological processes. Urinary exosomes have recently been 
described as treasure chests of information and a potential source of new cancer biomarkers including 
PCa [15]. Analyzing the content of exosomes harvested from urine has a number of advantages: (i) it is 
non-invasive; (ii) data is informative with regards to PCa diagnosis and potentially the status of overall 
tumor malignancy; (iii) the genetic and proteomic material within exosomes is protected from enzymic 
degradation by the exosomal lipid bilayer [177], and (iv) exosomes are stable after long-term storage at 
−80 °C, which makes prospective studies feasible. Further progress has been made in terms of storage, 
processing [178] and analysis of protein [22] and RNA content.  
To our knowledge no high-throughput technique has been used to analyze the RNA or protein 
content of urinary exosomes for PCa biomarker discovery in individual samples. However, some 
reports have indicated urinary exosomes to be an excellent source of PCa biomarkers. At a protein 
level, Mitchell PJ et al. [118] analyzed urinary exosomes from 10 healthy donors and 10 PCa patients 
who were undergoing hormonal therapy prior to radical radiotherapy. PSA and PSMA were found to 
be present in almost all of the PCa specimens, but not in the healthy donor specimens. At an RNA 
level, Nilsson et al. [179] showed that known RNA markers for PCa, such as TMPRSS2-ERG fusion 
transcripts and PCA3, could be detected in urine-derived and PCa cell line-derived exosomes by using 
Nested PCR [24]. This demonstrated a potential for diagnosis, as well as a strategy for the successful 
monitoring of the status of cancer patients. miRNAs have also been detected in extracellular fractions, 
stabilised by their encapsulation in microvesicles such as exosomes. Exosomes are thus a prime  
non-invasive source of biomarkers for cancer and other diseases [180]. 
3. Conclusions 
The introduction of PSA testing has radically altered how PCa is diagnosed and managed. However, 
controversy still exists regarding both the utility of PSA screening for reducing PCa mortality and the 
risks associated with PCa over-diagnosis. Furthermore, there is the problem of the heterogeneous 
nature of PCa foci and problem of adequately sampling and assessing foci of poor prognosis tumor. 
Additional markers are therefor urgently required to supplement or replace the PSA test and improve 
the specificity of PCa detection and prognosis. Multiplex urine-based assays could provide the answer 
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and have the advantage of potentially sampling PCa material from multiple tumor foci within 
individual prostates and providing both diagnostic and prognostic biomarkers [181]. 
It has been demonstrated that post-DRE urine samples are a rich source of biomarkers for PCa. 
Urine can be obtained in any urology clinic and does not require any change in routine clinical 
practices. Thus, post-DRE urine could be the best compromise between a minimally invasive 
technique and obtaining sufficient material for a correct diagnosis. However, to properly assess and 
validate promising urine candidates there needs to be large prospective studies of urine biomarkers 
using robust and standardized methods for urine collection, storage, harvest and analysis of DNA, 
RNA, miRNA, protein and metabolites. 
A future goal is therefore the development of a low cost, point of care, multiplexed, urine-based 
detection test for PCa which could be incorporated seamlessly into routine clinical practice to better 
determine which patients should undergo biopsy, and to highlight those patients that have a high risk 
of PCa metastasis/CRPC, and which therefor require treatment, at the earliest possible point in time 
(Figure 2). 
Figure 2. Current and future improvement in the PCa diagnostic scheme. 
 
In summary, the future of urine-based PCa biomarkers looks promising. It remains for us to validate 
the many exciting candidate biomarkers that have been discovered and to discover novel markers that 
will help to: (i) identify those men with indolent PCa, i.e., those who will not be affected by disease in 
their lifetimes and who do not need treatment; (ii) minimize the number of unnecessary PBs; (iii) identify 
men with aggressive disease, distinguishing between who will benefit from local therapy and those 
who are likely to fail local therapy and require adjuvant intervention; and (iv) find markers that may 
serve as surrogate end points for clinical progression or survival [182]. 
Another important point that needs to be addressed is the necessity of the DRE. In the future, we 
would like to know if urine samples provided without a DRE contain enough material to correctly 
detect prostate biomarkers and, thus, enable a correct diagnosis. Although DRE is part of the 
diagnostic tripod (PSA, DRE and biopsy), it is usually poorly tolerated by patients and always requires 
medical intervention. This detail may represent a limiting factor, since the urologist would need to 
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have the facilities to freeze and store urine samples before sending them to the laboratory. In large 
trials, the question of whether and how to perform the DRE to optimize sensitivity and specificity must 
be addressed for each potential marker [183]. 
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